Los Angeles Capital Management
ANIK icon

Los Angeles Capital Management’s Anika Therapeutics ANIK Stock Holding History

Los Angeles Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.45K Sell
100
-14,050
-99% -$163K ﹤0.01% 2322
2025
Q4 		$138K Sell
14,150
-11,980
-46% -$115K ﹤0.01% 1339
2025
Q3 		$246K Buy
+26,130
New +$250K ﹤0.01% 1203
2025
Q2 		– Sell
-11,800
Closed -$177K – 1328
2025
Q1 		$177K Buy
11,800
+100
+0.9% +$1.66K ﹤0.01% 1036
2024
Q4 		$193K Buy
11,700
+980
+9% +$19.3K ﹤0.01% 1061
2024
Q3 		$265K Sell
10,720
-1,300
-11% -$33.7K ﹤0.01% 1050
2024
Q2 		$304K Sell
12,020
-1,900
-14% -$49.2K ﹤0.01% 1008
2024
Q1 		$354K Hold
13,920
– – ﹤0.01% 963
2023
Q4 		$315K Hold
13,920
– – ﹤0.01% 1005
2023
Q3 		$259K Buy
13,920
+4,410
+46% +$91.5K ﹤0.01% 1002
2023
Q2 		$247K Sell
9,510
-200
-2% -$5.35K ﹤0.01% 1066
2023
Q1 		$279K Sell
9,710
-1,000
-9% -$29.8K ﹤0.01% 1029
2022
Q4 		$317K Sell
10,710
-13,250
-55% -$377K ﹤0.01% 1023
2022
Q3 		$570K Buy
23,960
+1,490
+7% +$34.3K ﹤0.01% 879
2022
Q2 		$502K Sell
22,470
-915
-4% -$20.4K ﹤0.01% 963
2022
Q1 		$587K Sell
23,385
-10,332
-31% -$315K ﹤0.01% 971
2021
Q4 		$1.21M Sell
33,717
-3,845
-10% -$154K ﹤0.01% 658
2021
Q3 		$1.6M Sell
37,562
-2,660
-7% -$110K 0.01% 588
2021
Q2 		$1.74M Sell
40,222
-12,655
-24% -$539K 0.01% 627
2021
Q1 		$2.16M Sell
52,877
-15,811
-23% -$600K 0.01% 595
2020
Q4 		$3.11M Sell
68,688
-16,992
-20% -$645K 0.01% 516
2020
Q3 		$3.03M Sell
85,680
-19,291
-18% -$697K 0.01% 453
2020
Q2 		$3.96M Buy
104,971
+7,695
+8% +$254K 0.02% 444
2020
Q1 		$2.81M Buy
97,276
+89,779
+1,198% +$3.63M 0.02% 455
2019
Q4 		$389K Buy
7,497
+1,030
+16% +$59.8K ﹤0.01% 1074
2019
Q3 		$355K Buy
+6,467
New +$332K ﹤0.01% 1082
2019
Q2 		– Sell
-12,016
Closed -$363K – 1341
2019
Q1 		$363K Sell
12,016
-4,270
-26% -$146K ﹤0.01% 1160
2018
Q4 		$547K Hold
16,286
– – ﹤0.01% 943
2018
Q3 		$687K Sell
16,286
-7,109
-30% -$281K ﹤0.01% 1009
2018
Q2 		$749K Sell
23,395
-100
-0.4% -$4.12K ﹤0.01% 1016
2018
Q1 		$1.17M Sell
23,495
-9,385
-29% -$530K 0.01% 785
2017
Q4 		$1.77M Buy
32,880
+10,804
+49% +$598K 0.01% 706
2017
Q3 		$1.28M Buy
22,076
+1,890
+9% +$98.8K 0.01% 742
2017
Q2 		$996K Buy
20,186
+100
+0.5% +$4.61K 0.01% 756
2017
Q1 		$873K Sell
20,086
-4,611
-19% -$220K 0.01% 759
2016
Q4 		$1.21M Buy
24,697
+8,100
+49% +$374K 0.01% 656
2016
Q3 		$794K Hold
16,597
– – 0.01% 784
2016
Q2 		$890K Sell
16,597
-5,668
-25% -$267K 0.01% 738
2016
Q1 		$996K Sell
22,265
-5,280
-19% -$214K 0.01% 624
2015
Q4 		$1.05M Buy
27,545
+7,340
+36% +$281K 0.01% 659
2015
Q3 		$643K Hold
20,205
– – 0.01% 809
2015
Q2 		$667K Buy
20,205
+920
+5% +$32.8K 0.01% 863
2015
Q1 		$794K Sell
19,285
-1,010
-5% -$40.8K 0.01% 800
2014
Q4 		$827K Buy
20,295
+7,555
+59% +$295K 0.01% 695
2014
Q3 		$467K Buy
+12,740
New +$551K 0.01% 796

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Los Angeles Capital Management's ANIK Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Anika Therapeutics (ANIK) stake by 99% in Q1 2026, selling an estimated $163K and leaving 100 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #2322.

Los Angeles Capital Management first reported a position in ANIK in Q3 2014 and has held it in 45 quarters since. The position peaked at $3.96M in Q2 2020. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Los Angeles Capital Management held 100 shares of Anika Therapeutics worth $1.45K as of Q1 2026.
  • Los Angeles Capital Management sold 14,050 Anika Therapeutics shares in Q1 2026, an estimated $163K.
  • Anika Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2322 holding.
  • Los Angeles Capital Management first reported a position in Anika Therapeutics in Q3 2014 and has held it in 45 quarters since.
  • Los Angeles Capital Management's Anika Therapeutics position peaked at $3.96M in Q2 2020.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.